Endologix Announces Podium Presentation on Ventana™ Stent Graft at VEITHsymposium 2010

IRVINE, Calif., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that a podium presentation on the Company's Ventana™ fenestrated stent graft will be given at the VEITHsymposium 2010 in New York by Daniel G. Clair, MD, Chairman, Cleveland Clinic Department of Vascular Surgery, Cleveland, OH, and co-chair of the VEITHsymposium.  Dr. Clair participated in the first implant of the Ventana stent graft earlier this month and will discuss the need for fenestrated stent grafts and the early clinical experience with Ventana in his presentation titled "Off-The-Shelf Fenestrated Device From Endologix For Treatment of Pararenal And Juxtarenal AAAs: Initial Clinical Experience."

In addition, Endologix will be hosting several physician presentations and hands-on product demonstrations at the Company's pavilion at the VEITHsymposium. These presentations are focused on Endologix's current and new product pipeline.

John McDermott, Endologix President and Chief Executive Officer, said, "We are very pleased that a number of thought leading physicians, including Dr. Clair, will be presenting their experience with our products at the VEITHsymposium next week.  We believe we have the most innovative new product pipeline in the aortic stent graft market, the strength of which will be evident by the many presentations and case demonstrations we have planned for the meeting.  We look forward to Dr Clair's presentation and sharing more information about our new product pipeline with physicians in the months ahead."

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements, including the planned expansion of Endologix's product portfolio, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the approval and success of sales efforts for new products, product research and development efforts, and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

SOURCE Endologix, Inc.